Frank spent the last 30 years in chief executive and top commercial roles with both established and emerging medical technology companies.

Frank started his career with GE Healthcare in diagnostics imaging and patient monitoring businesses, where he led company-wide marketing and strategic planning projects and supported a major M&A transaction. After that Frank served as Vice President at Roche Diagnostics leading global business development initiatives.

Subsequently for over seven years, Frank was Senior Vice President and the top commercial/operations leader at Stereotaxis, Inc., a publicly-traded company focusing on robotic surgery innovations for cardiac/vascular procedures, with product portfolio included a million-dollar robotic system and multiple FDA approved surgical disposables. The company achieved hundreds of million dollars in revenue during this period.

During 2019-2023, Frank was President & Chief Commercial Officer at Eyenuk, Inc., an innovative diagnostic company with autonomous AI technology that was FDA-cleared, Medicare-reimbursed, supported by a new Category 1 CPT code, and adopted around the world.

Before joining BlackLight Surgical, Frank led Caristo Diagnostics as CEO for about four years. Caristo has developed a portfolio of imaging-based and AI-assisted platforms for diagnosis of heart and vascular diseases. Caristo was named by Newsweek as one of world’s Best Digital Health Companies, and was selected by the World Economic Forum (WEF) as a Technology Pioneer. Under Frank’s leadership, Caristo received FDA de novo authorization for its coronary inflammation detection technology, and received FDA 510(k) clearance for its coronary plaque quantification technology. Caristo has been experiencing rapid commercial growth after American Medical Association approval of new CPT codes for Caristo technologies.